TY - JOUR T1 - Concomitant Medications and Clinical Outcomes in Idiopathic Pulmonary Fibrosis JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01188-2019 SP - 1901188 AU - Michael Kreuter AU - David J. Lederer AU - Vincent Cottin AU - Nicolas Kahn AU - Brett Ley AU - Carlo Vancheri AU - Derek Weycker AU - Mark Atwood AU - Klaus-Uwe Kirchgaessler AU - Christopher J. Ryerson Y1 - 2019/01/01 UR - http://erj.ersjournals.com/content/early/2019/08/29/13993003.01188-2019.abstract N2 - Patients with idiopathic pulmonary fibrosis (IPF) frequently have a substantial burden of comorbidities [1]. Antifibrotic therapy is recommended to slow the progression of IPF [2]. Patients receiving antifibrotic therapy frequently receive concomitant medications for the management of comorbidities [1, 3–9]. Previous post hoc analyses of antacids, statins, metformin, anti-coagulants and angiotensin modulators in patients with IPF enrolled in Phase III randomised controlled trials (RCTs) have generated hypotheses on the impact of these treatments on IPF outcomes [3–9]. The effects of multiple concomitant medications in patients with IPF have been largely unexplored. The objective of the present analyses was to explore the association between use of combinations of frequently prescribed concomitant medications and disease outcomes in patients with IPF.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Kreuter reports grants and personal fees from Boehringer Ingelheim, grants and personal fees from Galapagos, grants and personal fees from Roche, during the conduct of the study.Conflict of interest: Dr. Lederer reports personal fees from Fibrogen, personal fees from Galapagos, personal fees from Roche, personal fees from Global Blood Therapeutics, personal fees from Sanofi Genzyme, personal fees from Veracyte, during the conduct of the study.Conflict of interest: Dr. Cottin reports grants and personal fees from Boehringer Ingelheim, grants and personal fees from Roche, personal fees from Actelion, personal fees from Bayer, personal fees from Celgene, personal fees from Galapagos, personal fees from Gilead, personal fees from GlaxoSmithKline, personal fees from Merck Sharp & Dohme, personal fees from Novartis, personal fees from Promedior, personal fees from Sanofi, during the conduct of the study.Conflict of interest: Dr. Kahn reports grants and personal fees from Boehringer Ingelheim, grants and personal fees from Roche, during the conduct of the study.Conflict of interest: Dr. Ley reports personal fees from Roche/Genentech, during the conduct of the study.Conflict of interest: Dr. Vancheri reports grants and personal fees from Boehringer Ingelheim, personal fees from Chiesi Farmaceutici , grants and personal fees from Roche, during the conduct of the study.Conflict of interest: Dr. Weycker reports and Employee of Policy Analysis Inc. (PAI).Conflict of interest: Dr. Atwood reports and Employee of Policy Analysis Inc. (PAI).Conflict of interest: Dr. Kirchgaessler reports and Employee of F. Hoffmann-La Roche Ltd.Conflict of interest: Dr. Ryerson reports grants and personal fees from Boehringer Ingelheim, grants and personal fees from Roche, during the conduct of the study. ER -